Earlier in August, we highlighted Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) as being a company to watch going forward, with a specific focus on the company’s pipeline. We noted that ...

I will not discuss the various approaches, rather I will concentrate on the work being done by ADAP and its alliance partnerships. But I list below a few drugs that have been approved by the FDA ...

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops ...

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade FDA approves Adaptimmune Therapeutics' Tecelra ...

Adaptimmune Therapeutics PLC (ADAP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

This reverses the recent trend for ADAP, as the stock is now up over 4% in the past one-month time frame. The clinical-stage biopharmaceutical company has seen a flat track record when it comes to ...

Adaptimmune Therapeutics ADAP is a clinical-stage biopharmaceutical company focused on developing novel T-cell therapies targeting cancer indications. The most advanced candidate in the company ...

Adaptimmune Therapeutics (NASDAQ:ADAP) just reported results for the second quarter of 2024. Adaptimmune Therapeutics reported earnings per share of 24 cents. This was above the analyst estimate ...